ViTToria Biotherapeutics, a company co-founded by Marco Ruella, MD, an Assistant Professor of Medicine at Penn Medicine and the scientific director of the lymphoma program at Penn Medicine’s Abramson Cancer Center, secured over $15 million in a private financing round to support the development of novel CAR T cell therapies. The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, a CAR T cell therapy for T-cell Lymphoma, into the clinic. ViTToria is focused on developing novel CAR T cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from Penn, the company’s proprietary Senza5 platform is designed to improve the efficacy of engineered T cell therapies with pipeline applications in oncology and autoimmune diseases. Read more about ViTToria and its recent funding here.